Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CCT5069 | Other Identifier | OnCore |
Not provided
Not provided
Not provided
No participants enrolled
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Neuropsychological testing | Other | Participants will take neuropsychological testing in-person or via telehealth video |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Neuropsychological testing | Behavioral | Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients who complete neuropsychological testing in the post-CAR-T adult population | 6 months | |
| Number of patients who complete telehealth neuropsychological testing in the post-CAR-T adult | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Wechsler Test of Adult Reading WTAR Neuropsychological testing | The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data. | Baseline |
| Hopkins Verbal Learning Test HVLT |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brian Scott, MD | Stanford University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford Cancer Center | San Francisco | California | 94305 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data. |
| Baseline |
| Controlled Oral Work Association Test COWAT | The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data. | Baseline |
| Trails A and B (Oral Trails) | The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data. | Baseline |
| Digit Span | The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data. | Baseline |
| Clock Drawing Test | The neuropsychological testing will capture any potential deficits in language, processing speed, executive functioning and visuospatial abilities, and may be compared to age and education-matched normative data. | Baseline |
| Short form of Quality of Life SF-36 | Items from the SF36 (Short Form 36) survey | Baseline |
| General Anxiety Disorder Assessment GAD-7 | Assesses anxiety symptoms The following cut-offs correlate with level of anxiety severity: Score 0-4: Minimal Anxiety, Score 5-9: Mild Anxiety, Score 10-14: Moderate Anxiety, Score greater than 15: Severe Anxiety | Baseline |
| Patient Health Questionnaire PHQ9 | Assesses depressive symptoms PHQ-9 Score 0 - 4 None, Mild= 5 - 9 , Moderate=10 - 14 , Moderately Severe=15 - 19 , Severe=20 - 27 | Baseline |
| ID | Term |
|---|---|
| D008228 | Lymphoma, Non-Hodgkin |
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D009483 | Neuropsychological Tests |
| ID | Term |
|---|---|
| D011581 | Psychological Tests |
| D004191 | Behavioral Disciplines and Activities |
Not provided
Not provided